Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer

Multicentric analytical and inter-observer comparability of four clinically developed programmed death-ligand 1 immunohistochemistry assays in advanced clear cell renal cell carcinoma

(2020) Ulrich Sommer et al.   Clinical Genitourinary Cancer

Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update

(2020) Kimberly H. Allison et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab for Early Triple-Negative Breast Cancer

(2020) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer

(2020) Emily S. Reisenbichler et al.   MODERN PATHOLOGY

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†

(2020) F. Cardoso et al.   ANNALS OF ONCOLOGY

A multicentre analytical comparison study of inter‐reader and inter‐assay agreement of four programmed death‐ligand 1 (PD‐L1) immunohistochemistry assays for scoring in triple‐negative breast cancer

(2020) Aurelia Noske et al.   HISTOPATHOLOGY

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

(2020) Elizabeth A Mittendorf et al.   LANCET

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

(2020) Javier Cortes et al.   LANCET

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Interobserver and Intraobserver agreement of PD-L1 scoring in Head and Neck Squamous Cell Carcinoma (HSCC), Urothelial Carcinoma (UC), and Breast Carcinoma (BC)

(2019) Michelle R Downes et al.   HISTOPATHOLOGY

Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays

(2019) Kristina Schwamborn et al.   VIRCHOWS ARCHIV

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

(2019) Aurelien Marabelle et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Peter Schmid et al.   LANCET ONCOLOGY

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

(2018) Karina Kulangara et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics

(2018) Margarita Udall et al.   Diagnostic Pathology

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

(2018) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

(2018) Bharathi Vennapusa et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types

(2018) Chiyun Wang et al.   HUMAN PATHOLOGY

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer

(2017) Andreas H Scheel et al.   HISTOPATHOLOGY

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer

(2017) David L. Rimm et al.   JAMA Oncology

Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies

(2016) Woo Young Sun et al.   Journal of Translational Medicine